ONCR Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 Dec 2023 @ 14:55):

Stats
Today's Volume	135 947
Average Volume	108 675
Market Cap	3.29M
EPS	$0 ( 2024-03-21 )
Next earnings date	( $0 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0362
ATR14	$0.00400 (3.17%)

Insider Trading

Date	Person	Action	Amount	type
2023-06-06	Shea Brian J.	Sell	0	Common Stock
2023-06-06	Shea Brian J.	Sell	15 000	Employee Stock Option (right to buy)
2023-06-06	Shea Brian J.	Sell	3 744	Employee Stock Option (right to buy)
2023-06-06	Shea Brian J.	Sell	14 700	Employee Stock Option (right to buy)
2023-06-06	Shea Brian J.	Sell	19 100	Employee Stock Option (right to buy)

INSIDER POWER
-36.44
Last 97 transactions
Buy: 2 441 000 \| Sell: 694 654

Volume Correlation

Long: 0.41 (neutral)

Short: 0.27 (neutral)

Signal:(89.911) Neutral

Oncorus, Inc. Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Oncorus, Inc. Correlation - Currency/Commodity

-0.05
( neutral )

-0.17
( neutral )

0.00
( neutral )

-0.06
( neutral )

-0.53
( weak negative )

0.29
( neutral )

Oncorus, Inc. Financials

Annual	2022
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-3.02

Q1	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-1.280

Q4	2022
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.830

Q3	2022
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.770

Financial Reports:

No articles found.

Oncorus, Inc.

Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various cancers. It is also developing ONCR-GBM, a preclinical stage oHSV program for treating brain cancer through intratumoral injection; and synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus. The company has a clinical trial collaboration and supply agreement with MSD International GmbH to evaluate the safety and tolerability of ONCR-177 combined with Merck's cancer immunotherapy KEYTRUDA in its Phase 1 clinical trial in patients with solid tumors. Oncorus, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.